FDA Reviews and Approvals, Commercialization, Integrations, and Top-Line Results - Research Report on Bristol-Myers Squibb, Medtronic, Boston Scientific, Varian, and Rockwell Medical Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, July 17, 2013 NEW YORK, July 17, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Medtronic, Inc. (NYSE: MDT), Boston Scientific Corporation (NYSE: BSX), Varian Medical Systems, Inc. (NYSE: VAR), and Rockwell Medical, Inc. (NASDAQ: RMTI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Bristol-Myers Squibb Company Research Report On July 11, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) announced that the US Food and Drug Administration (FDA) has accepted for review a Supplemental New Drug Application (sNDA) for Eliquis (apixaban). Bristol-Myers Squibb reported that Eliquis (apixaban) is for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. The Company also reported that the Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is March 15, 2014. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/88a2_BMY] -- Medtronic, Inc. Research Report On July 11, 2013, Medtronic, Inc. (Medtronic) announced the global market introduction of the CD HORIZON SOLERA Spinal System Sagittal Adjusting Screw (SAS), which may be used in the surgical correction of complex spinal pathologies. According to Medtronic, the SAS features a fixed head made of cobalt chrome that contains a sliding saddle which gives surgeons the ability to position the SAS in the natural kyphotic (outward) and lordotic (inward) curves of the spine. Doug King, Senior Vice President and President of Medtronic Spinal at Medtronic, said, "The Sagittal Adjusting Screw is another key element in enhancing the capability of our CD HORIZON SOLERA pedicle fixation system." King added, "It brings new innovation to the market and extends our industry-leading portfolio of spinal therapies." The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/b199_MDT] -- Boston Scientific Corporation Research Report On July 12, 2013, Boston Scientific Corporation (Boston Scientific) announced that it has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla Guide Extension Catheter and has launched the device in the US and Europe. Kevin Ballinger, President of Interventional Cardiology at Boston Scientific, stated, "Boston Scientific is committed to delivering innovative technologies such as the Guidezilla device that enable physicians to improve outcomes for patients undergoing complex coronary interventions." Ballinger continued, "The Guidezilla guide extension catheter is a specialty device that provides physicians another compelling tool to help treat difficult lesions." The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/5649_BSX] -- Varian Medical Systems, Inc. Research Report On July 8, 2013, Varian Medical Systems, Inc. (Varian) announced that it has successfully integrated its Eclipse treatment planning system with Elekta linear accelerators to deliver VMAT treatments at Kantonsspital St. Gallen in Switzerland. Dr. Ludwig Plasswilm, Chief of Radiation Oncology at Kantonsspital St. Gallen, commented, "Physicists at our department worked on the development of this new approach with Varian, which has demonstrated its commitment to open architecture for clinical systems, and we have now seen successful integration of Eclipse with our treatment machines." Plasswilm added, "We have now initiated more advanced volumetric treatments and our experience so far is that the integration is very good with a natural workflow. We haven't experienced any problems and are delighted to be the first in the world to integrate these systems for the benefit of our patients." The Full Research Report on Varian Medical Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/b046_VAR] -- Rockwell Medical, Inc. Research Report On July 11, 2013, Rockwell Medical, Inc. (Rockwell Medical) announced top-line results from its long-term CRUISE-1 Phase 3 efficacy study of SFP. Rob Chioini, Founder, Chairman, and CEO of Rockwell Medical, said, "We are thrilled with the successful results of this CRUISE-1 efficacy study. In addition to demonstrating statistical significance and meeting the primary efficacy endpoint, the data show that in place of IV iron, SFP is a safe and effective iron replacement therapy that consistently maintains hemoglobin levels without increasing iron stores. These successful results, coupled with the recent positive PRIME study data demonstrating SFP's ability to significantly reduce ESA use, support our belief that SFP will set a new paradigm in iron therapy treatment for hemodialysis patients. We believe SFP is positioned to become the new standard of care in iron therapy. We anticipate confirmatory and successful results from the CRUISE-2 trial, which is nearing completion." The Full Research Report on Rockwell Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/3e79_RMTI] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
FDA Reviews and Approvals, Commercialization, Integrations, and Top-Line Results - Research Report on Bristol-Myers Squibb,
Press spacebar to pause and continue. Press esc to stop.